BACKGROUND: Identification of risk factors for BK virus (BKV) replication may improve transplant outcome. We investigated the impact of immunosuppressive drugs on the prevalence of BKV replication in recipients of human renal allografts. METHODS: One hundred twenty renal allograft recipients were studied prospectively at 1, 3, and 6 months posttransplantation to identify risk factors for BKV replication. BKV replication was quantified by measurement of urinary cell BKV VP1 mRNA levels using BKV specific primers and TaqMan probe in a real-time quantitative polymerase chain reaction assay. Levels of urinary cell mRNA for granzyme B, CD103, and transforming growth factor-beta1 were measured to ascertain whether BKV replication is associated with an inflammatory signature. RESULTS: The prevalence of BKV replication increased over time and was highest at 6 months compared with 1 or 3 months posttransplantation (P<0.001). A logistic regression model analysis demonstrated that steroid maintenance therapy (odds ratio: 8.3, P=0.003) and induction with rabbit anti-human thymocyte globulin (odds ratio: 5.8, P=0.008) were independent risk factors for BKV replication. Neither mycophenolate mofetil dose nor tacrolimus dose or trough levels were different between those with or without BKV replication. The development of acute rejection or antirejection treatment with methylprednisolone did not increase the risk of BKV replication. BKV replication was associated with heightened levels of urinary cell mRNA for granzyme B (P<0.002), CD103 (P<0.005) but not for transforming growth factor-beta1 (P>0.05). CONCLUSIONS: Steroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for BKV replication in renal allograft recipients treated with tacrolimus and mycophenolate mofetil.
BACKGROUND: Identification of risk factors for BK virus (BKV) replication may improve transplant outcome. We investigated the impact of immunosuppressive drugs on the prevalence of BKV replication in recipients of human renal allografts. METHODS: One hundred twenty renal allograft recipients were studied prospectively at 1, 3, and 6 months posttransplantation to identify risk factors for BKV replication. BKV replication was quantified by measurement of urinary cell BKVVP1 mRNA levels using BKV specific primers and TaqMan probe in a real-time quantitative polymerase chain reaction assay. Levels of urinary cell mRNA for granzyme B, CD103, and transforming growth factor-beta1 were measured to ascertain whether BKV replication is associated with an inflammatory signature. RESULTS: The prevalence of BKV replication increased over time and was highest at 6 months compared with 1 or 3 months posttransplantation (P<0.001). A logistic regression model analysis demonstrated that steroid maintenance therapy (odds ratio: 8.3, P=0.003) and induction with rabbit anti-human thymocyte globulin (odds ratio: 5.8, P=0.008) were independent risk factors for BKV replication. Neither mycophenolate mofetil dose nor tacrolimus dose or trough levels were different between those with or without BKV replication. The development of acute rejection or antirejection treatment with methylprednisolone did not increase the risk of BKV replication. BKV replication was associated with heightened levels of urinary cell mRNA for granzyme B (P<0.002), CD103 (P<0.005) but not for transforming growth factor-beta1 (P>0.05). CONCLUSIONS:Steroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for BKV replication in renal allograft recipients treated with tacrolimus and mycophenolate mofetil.
Authors: B Li; C Hartono; R Ding; V K Sharma; R Ramaswamy; B Qian; D Serur; J Mouradian; J E Schwartz; M Suthanthiran Journal: N Engl J Med Date: 2001-03-29 Impact factor: 91.245
Authors: F Ginevri; R De Santis; P Comoli; N Pastorino; C Rossi; G Botti; I Fontana; A Nocera; M Cardillo; M R Ciardi; F Locatelli; R Maccario; F Perfumo; A Azzi Journal: Transplantation Date: 2003-04-27 Impact factor: 4.939
Authors: Helen B Viscount; Albert J Eid; Mark J Espy; Matthew D Griffin; Kristine M Thomsen; William S Harmsen; Raymund R Razonable; Thomas F Smith Journal: Transplantation Date: 2007-08-15 Impact factor: 4.939
Authors: Hans H Hirsch; Wendy Knowles; Michael Dickenmann; Jakob Passweg; Thomas Klimkait; Michael J Mihatsch; Jürg Steiger Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Ruchuang Ding; Mara Medeiros; Darshana Dadhania; Thangamani Muthukumar; David Kracker; Jin M Kong; Susanna R Epstein; Vijay K Sharma; Surya V Seshan; Baogui Li; Manikkam Suthanthiran Journal: Transplantation Date: 2002-10-15 Impact factor: 4.939
Authors: Tobias Bethge; Helen A Hachemi; Julia Manzetti; Rainer Gosert; Walter Schaffner; Hans H Hirsch Journal: J Virol Date: 2015-01-14 Impact factor: 5.103
Authors: George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna Journal: Clin Microbiol Rev Date: 2017-04 Impact factor: 26.132
Authors: Isaac E Hall; Peter Philip Reese; Sherry G Mansour; Sumit Mohan; Yaqi Jia; Heather R Thiessen-Philbrook; Daniel C Brennan; Mona D Doshi; Thangamani Muthukumar; Enver Akalin; Meera Nair Harhay; Bernd Schröppel; Pooja Singh; Francis L Weng; Jonathan S Bromberg; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2021-03-10 Impact factor: 8.237
Authors: H H Hirsch; F Vincenti; S Friman; M Tuncer; F Citterio; A Wiecek; E H Scheuermann; M Klinger; G Russ; M D Pescovitz; H Prestele Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086